title: An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B.
abstract: We compared the characteristics of psoralen and ultraviolet A (PUVA) erythema in skin photosensitized by bath or oral methoxsalen in 20 subjects. Erythema was assessed visually and with a reflectance instrument at 24 h intervals for 7 days. In addition, narrowband ultraviolet B (TL-01 UVB) erythema was examined in 19 of these subjects at 4, 8, 12, 24, 48 and 72 h and in another nine subjects at 12, 15, 18, 21 and 24 h. Both bath and oral PUVA exhibited broad erythemal peaks beyond 72 h. For topical PUVA the lowest minimal phototoxic dose (MPD) occurred at 120 and 144 h (P = 0.01 and 0.03 compared with 72 h). Oral PUVA erythema peaked earlier at 96 h: the MPD was significantly lower at 96, 120 and 144 h compared with 72 h (P = 0.001, 0.01 and 0.02, respectively). At 120 h, bath PUVA had a significantly steeper slope compared with oral PUVA. The TL-01 UVB minimal erythema dose was significantly lower at 12 h compared with 24 h (P = 0.019). The majority of subjects were at maximal erythema at 12 h (22 of 28) and 15 h (eight of nine). Our results suggest that peak erythema for bath PUVA, oral PUVA and TL-01 UVB occurs at 120, 96 and 12-15 h, respectively.
authors.affiliation: Photobiology Unit, Department of Dermatology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
authors.forename: Irene
authors.initials: I
authors.lastname: Man
authors.forename: Robert S
authors.initials: RS
authors.lastname: Dawe
authors.forename: James
authors.initials: J
authors.lastname: Ferguson
authors.forename: Sally H
authors.initials: SH
authors.lastname: Ibbotson
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D004890:Erythema / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D006801:Humans; D008730:Methoxsalen / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011701:PUVA Therapy; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects*; D014467:Ultraviolet Therapy / Q000009:adverse effects*
chemical_list: D017319:Photosensitizing Agents; D008730:Methoxsalen